Deuterated bile acids

Abstract

This disclosure relates to deuterated bile acid compositions. A deuterated compound is selected from the disclosed groups of bile acids and their derivatives, analogs and salts. At least one of the hydrogen atoms in the compound is replaced with deuterium.

1 . A deuterated compound selected from the group consisting of: 
       
         
           
           
               
               
           
         
         
           
           
               
               
           
         
       
       wherein at least one of elements R 1 -R xx  comprises deuterium. 
     
     
         2 . The deuterated compound of  claim 1 , wherein the compound is water-soluble. 
     
     
         3 . The deuterated compound of  claim 1 , wherein the compound is a salt. 
     
     
         4 . The deuterated compound of  claim 1 , wherein the compound is hydrophobic. 
     
     
         5 . The deuterated compound of  claim 1 , wherein the compound has pro-drugs, derivatives and conjugates used for the treatment or prevention of any degenerative disorders in humans. 
     
     
         6 . The deuterated compound of  claim 1 , wherein the compound has deuterium enrichment of at least 5%. 
     
     
         7 . The deuterated compound of  claim 6 , wherein the compound has deuterium enrichment of at least 10%. 
     
     
         8 . The deuterated compound of  claim 7 , wherein the compound has deuterium enrichment of at least 30%. 
     
     
         9 . The deuterated compound of  claim 8 , wherein the compound has deuterium enrichment of at least 50%. 
     
     
         10 . The deuterated compound of  claim 9 , wherein the compound has deuterium enrichment of at least 70%. 
     
     
         11 . The deuterated compound of  claim 1 , wherein the compound has the structure of formula I, and wherein the compound has deuterium enrichment of at least 90%. 
     
     
         12 . The deuterated compound of  claim 10 , wherein in the compound has deuterium enrichment of at least 98%. 
     
     
         13 . The deuterated compound of  claim 1 , wherein the compound has a structure selected from the group consisting of formulae I, II and III, and wherein the compound comprises one or more PO 4  groups. 
     
     
         14 . The deuterated compound of  claim 1 , wherein the compound has a structure selected from the group consisting of formulae I, II and III, and wherein the compound is chemically conjugated to a pro-drug of dopaminergic neurons. 
     
     
         15 . The deuterated compound of  claim 1 , wherein the compound has a structure selected from the group consisting of formulae I, II and III, and wherein the compound is chemically conjugated to a monoamine oxidase inhibitor. 
     
     
         16 . The deuterated compound of  claim 1 , wherein the compound has a structure selected from the group consisting of formulae I, II and III, and wherein the compound is chemically conjugated to a glutamate receptor antagonists. 
     
     
         17 . The deuterated compound of  claim 1 , wherein the compound has a structure selected from the group consisting of formulae I, II and III, and wherein the compound is chemically modified to function as an antioxidant. 
     
     
         18 . The deuterated compound of  claim 1 , wherein the deuterated compound is 
       
         
           
           
               
               
           
         
       
       or a structural analog thereof. 
     
     
         19 . The deuterated compound of  claim 18 , wherein R 6  is deuterium. 
     
     
         20 . The deuterated compound of  claim 18 , wherein R 12  is deuterium.